Diagnostics company receives additional
A continuation of work that Insight Genetics began with the NCI in 2012, the
According to the
“ROS1, RET and DEPDC1 are important biomarkers in the fight to improve outcomes for those with lung cancer,” said
Companion diagnostic tests such as those Insight Genetics is developing allow physicians to screen cancer patients for particular biomarkers, such as genetic mutations or dysregulation of gene expression. The results can indicate if a targeted therapy is more likely to be effective for a patient and provide indication on the most tolerable and effective dose. Such tests also can help physicians monitor the ongoing effectiveness of targeted medications and help them to determine when a new treatment might be necessary.
There are several therapies targeting RET and ROS1 with fewer yet also promising strategies against DEPDC1 in development. ARIAD’s Iclusig® (ponatinib), Bayer’s Nexavar® (sorafenib), and Exelexis’ Cometriq® (cabozantinib) target RET. Compounds at different stages of clinical development that target ROS1 include Pfizer’s Xalkori® (crizotinib), ARIAD’s AP26113, Synta’s HSP90 inhibitor ganetespib, and Xcovery’s X-396. DEPDC1/MPHOSH1 peptide vaccines are currently in Phase I/II clinical trials. Unfortunately, there are currently no regulatory-approved, high-throughput commercial diagnostics to reliably and efficiently identify these biomarkers.
As part of its Phase II contract, Insight Genetics will continue analytical and clinical validation of its three real-time qPCR-based NSCLC assays: Insight ROS Screen™, Insight RET Screen™, and Insight DEPDC1 Screen™. Initial experiments have demonstrated that these proprietary tests are highly sensitive and specific, offering results within 24 hours. This is a significant contrast to fluorescence in situ hybridization (FISH) detection assays for ROS1 and RET, which are costly, typically less sensitive, and take between 3-7 days to provide results.
This SBIR award is Insight Genetics’ fifth contract and second consecutive Phase II contract from NCI’s
About Insight Genetics
Insight Genetics is dedicated to improving the lives of cancer patients through advanced molecular diagnostics that enable precision in cancer care. The company specializes in the discovery, development and commercialization of companion diagnostics that detect specific cancer biomarkers and assist in guiding the effective diagnosis and treatment of cancer. Insight partners with leading academic researchers, pharmaceutical and biotechnology companies, clinical reference laboratories, and IVD kit manufacturers to create new standards of care for cancer patients worldwide. www.insightgenetics.com